Misophonia Has Genetic Links to Depression And Anxiety, Study Finds
Most of us can relate to feeling uncomfortable when someone scrapes their nails down a chalkboard. For those suffering the condition misophonia, sounds like slurping, snoring, breathing, and chewing and draw an equally stressful response.
A study published in 2023 by researchers in the Netherlands suggests the condition shares genes with mood disorders such as anxiety, depression, and PTSD.
University of Amsterdam psychiatrist Dirk Smit and colleagues analyzed the genetic data from the Psychiatric Genomics Consortium, UK Biobank, and 23andMe databases and found people who self-identified as having misophonia were more likely to have genes associated with psychiatric disorders, as well as tinnitus.
Watch the clip below for a summary on their findings.
Patients with tinnitus – a persistent, shrill ringing in the ears – are also more likely to have psychological symptoms of depression and anxiety.
"There was also an overlap with PTSD genetics," Smit told Eric W. Dolan at PsyPost.
"This means that genes that give a sensitivity to PTSD also increase the likelihood for misophonia, and that could point to a shared neurobiological system that affects both. And that could suggest that treatment techniques used for PTSD could also be used for misophonia."
This doesn't mean misophonia and these other conditions necessarily have shared mechanisms, only that some of the genetic risk factors may be similar.
Previous research found people who experience misophonia are more likely to internalize their distress. Smit and team's research, published in 2023, also backed this up, showing strong links with personality traits such as worry, guilt, loneliness, and neuroticism.
Responses to a triggering sound can range from irritation and anger to distress that interferes with everyday life.
"It has been argued… that misophonia is based on the feelings of guilt about the evoked irritation and anger rather than behavioral expressions of anger itself that causes the distress," write Smit and team.
People with autism spectrum disorder ( ASD) were less likely to experience misophonia. This was unexpected as those with ASD have a decreased tolerance to sounds.
"Our results suggest that misophonia and ASD are relatively independent disorders with regard to genomic variation," the researchers write in their paper.
"It raises the possibility that other forms of misophonia exist, one that is mostly driven by conditioning of anger or other negative emotionality to specific trigger sounds moderated by personality traits."
Smit and colleagues caution their data was mostly European so the same links may not show up in different populations. What's more, misophonia was not medically diagnosed in their data samples, only self-reported which may also skew the results.
But their study also provides clues for where further research could focus to find the biological mechanism behind misophonia. A 2023 survey suggests misophonia is more prevalent than previously thought, making studies like this one invaluable for understanding how our perception of the world links with our mind's ability to cope within it.
This research was published in Frontiers in Neuroscience.
An earlier version of this article was published in October 2024.
Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial
Leprosy Was Lurking in The Americas Long Before Colonization, Study Finds
Does Retinol Reverse Signs of Aging? Here's The Science.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
Yahoo
3 hours ago
- Yahoo
Private Japanese lunar lander heads toward a touchdown in the moon's far north
A private lunar lander from Japan is closing in on the moon, aiming for a touchdown in the unexplored far north with a mini rover. The moon landing attempt by Tokyo-based company ispace on Friday Japan time is the latest entry in the rapidly expanding commercial lunar rush. The encore comes two years after the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience holds a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house that will be lowered onto the moon's dusty surface. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another U.S. company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience is targeting the top of the moon, a less forbidding place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Once settled with power and communication flowing, the 7.5-foot (2.3-meter) Resilience will lower the piggybacking rover onto the lunar surface. Made of carbon fiber-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sports a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just 11 pounds (5 kilograms), will stick close to the lander, going in circles at a speed of less than one inch (a couple centimeters) per second. Besides science and tech experiments, there's an artistic touch. The rover holds a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg, for placement on the lunar surface. Takeshi Hakamada, CEO and founder of ispace, considers the latest moonshot 'merely a steppingstone,' with its next, much bigger lander launching by 2027 with NASA involvement, and even more to follow. 'We're not trying to corner the market. We're trying to build the market,' Jeremy Fix, chief engineer for ispace's U.S. subsidiary, said at a conference last month. 'It's a huge market, a huge potential." Fix noted that ispace, like other businesses, does not have 'infinite funds' and cannot afford repeated failures. While not divulging the cost of the current mission, company officials said it's less than the first one which exceeded $100 million. Two other U.S. companies are aiming for moon landings by year's end: Jeff Bezos' Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the U.S., China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
3 hours ago
- Yahoo
'80s Rocker's Choice of Shirt at Concert Has People Going Wild
'80s Rocker's Choice of Shirt at Concert Has People Going Wild originally appeared on Parade. Duran Duran guitarist John Taylor, 64, is inspiring some major comments section conversation with his recent on-stage fashion choice. The fashion-forward '80s band has always been trailblazers when it comes to style, but Taylor's latest choice has some wondering if it's time for the band to get a new a recent video shared to social media, Taylor can be seen onstage in black leather jeans and a light-colored, long-sleeve wrap top with a deep V-neck that stops just above his midriff. Fans found the funny in Taylor's choice of attire, with one hilariously writing, 'What in the rock and roll wrap top grandma is going on here?' Taylor's legions of fans continued to channel their comedy writer vibes with more hilarious commentary. One questioned, 'Did they stop by TJ Maxx on the way there..?', while another quipped, 'Lovely blouse.'Regardless of Taylor's wrap-top affinity, fans were still quick to note what a terrific bass player he is. One wrote, 'Exceptional musician. Gifted bassist,' and another shared, 'Insanely good bass player.' We couldn't agree more. Duran Duran is currently in the midst of a European tour, which is scheduled to end on July 9, 2025 in Spain. 🎬SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox🎬 '80s Rocker's Choice of Shirt at Concert Has People Going Wild first appeared on Parade on Jun 3, 2025 This story was originally reported by Parade on Jun 3, 2025, where it first appeared.
